Janni Mirosevich
About
In The Last Decade
Janni Mirosevich
18 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 79
- Molecular Biology 866
- Pulmonary and Respiratory Medicine 626
- Oncology 342
- Cancer Research 236
- Genetics 220
Countries citing papers authored by Janni Mirosevich
This map shows the geographic impact of Janni Mirosevich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janni Mirosevich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janni Mirosevich more than expected).
Fields of papers citing papers by Janni Mirosevich
This network shows the impact of papers produced by Janni Mirosevich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janni Mirosevich. The network helps show where Janni Mirosevich may publish in the future.
Co-authorship network of co-authors of Janni Mirosevich
This figure shows the co-authorship network connecting the top 25 collaborators of Janni Mirosevich. A scholar is included among the top collaborators of Janni Mirosevich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janni Mirosevich. Janni Mirosevich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 10 | |
| 2 | 20 | |
| 3 | 7 | |
| 4 | 2 | |
| 5 | 30 | |
| 6 | 78 | |
| 7 | A randomized phase II neoadjuvant trial in patients with stages II-III and inflammatory breast cancer. | 2 |
| 8 | Dasatinib (BMS-354825), a novel multi-targeted kinase inhibitor that blocks tumor cell migration and invasion, is a promising therapeutic agent for metastatic prostate cancer | 2 |
| 9 | 38 | |
| 10 | 76 | |
| 11 | 117 | |
| 12 | 308 | |
| 13 | 155 | |
| 14 | 78 | |
| 15 | 215 | |
| 16 | 203 | |
| 17 | 8 | |
| 18 | 53 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.